← Back to Clinical Trials
Recruiting Phase 2 NCT05940324

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

Trial Parameters

Condition Obsessive-Compulsive Disorder
Sponsor Stanford University
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 150
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2024-02-24
Completion 2028-11
Interventions
KetamineNaltrexone PillPlacebo pill

Brief Summary

The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.

Eligibility Criteria

Eligibility Criteria for Participants with OCD: Inclusion Criteria: * Ages 18-65 * Meet the criteria for OCD diagnosis * Failed at least 1 prior trial of standard first-line OCD treatment * Agree to the following lifestyle modifications: comply with requirements for fasting prior to the Experimental Session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures. * Able to provide informed consent Exclusion Criteria: * prior naltrexone or ketamine use/exposure * Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician * Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control * the presence of metal in the body that is contraindicated for MRI scans Eligibility Criteria for Healthy Volunteers: Inclusion Criteria: * Ages 18-65 * Able to provide informed consent Exclusion Criteria: * cur

Related Trials